Doroftei Bogdan, Ilie Ovidiu-Dumitru, Dabuleanu Ana-Maria, Diaconu Roxana, Maftei Radu, Simionescu Gabriela, Ilea Ciprian
Faculty of Medicine, University of Medicine and Pharmacy "Grigore T. Popa", University Street, no 16, 700115 Iasi, Romania.
Clinical Hospital of Obstetrics and Gynecology "Cuza Voda", Cuza Voda Street, no 34, 700038 Iasi, Romania.
Medicina (Kaunas). 2021 Apr 14;57(4):379. doi: 10.3390/medicina57040379.
: The latest reports suggest that follitropin delta is a highly efficient recombinant human follicle-stimulating hormone (r-hFSH) that became a part of the current assisted reproductive technologies (ARTs). Therefore, the present study aims to assess a series of parameters (follicles, oocytes, and embryos) and further by the outcomes in women following the administration of follitropin delta. : This observational study included 205 women. They were aged between 21 and 43 years (mean 33.45) and an anti-Müllerian hormone (AMH) level ranging from 0.11 to 16.00 ng/dL (mean 2.89). : In accordance with the established methodology and following the centralization of data, a total of fifty-eight pregnancies (28.29%) were achieved; forty-five (36.88%) were achieved in women under 35 years and thirteen (15.66%) in women above 35 years. These figures are positively correlated with women's age considering that the number of follicles >18 mm, oocytes fertilized and embryo(s) varies among groups. Regarding the interest parameters, we noted = 1719 follicles > 18 mm, = 1279 retrieved oocytes, and = 677 embryos at day 3. On the other hand, the following figures have been registered in women above 35 years: 814-follicles > 18 mm, 612 oocytes retrieved and 301 embryos at day 3. During this study, we registered only three cases of abortions ( = 1-0.81% in women under 35 years and = 2-2.40% in women above 35 years). Nine pregnancies (7.37%) were stopped from evolution in females under 35 years, and twelve pregnancies ( = 8-6.55% in women under 35 years, while = 4 in women above 35 years) were unsuccessful. A twin pregnancy has been confirmed (1.20%) in women above 35 years, six ongoing pregnancies (4.91%) in those under 35 years, and two in both groups (one per group- = 1-0.81%, and 1.20%- 1) in which we did not know the exact result were registered at the end of the established studied interval. However, there were also situations in which the treatment cause an over-reactivity or had no effect; 2 were non-responders, and 1 exhibited moderate ovarian hyperstimulation syndrome (OHSS). : Based on our results, we strongly encourage the use of this recombinant gonadotropin on a much larger scale.
最新报告表明，重组促卵泡素δ是一种高效的重组人促卵泡激素（r-hFSH），已成为当前辅助生殖技术（ART）的一部分。因此，本研究旨在评估一系列参数（卵泡、卵母细胞和胚胎），并进一步观察重组促卵泡素δ给药后女性的治疗结果。
这项观察性研究纳入了205名女性。她们的年龄在21至43岁之间（平均33.45岁），抗苗勒管激素（AMH）水平在0.11至16.00 ng/dL之间（平均2.89）。
按照既定方法并在数据集中化之后，总共实现了58例妊娠（28.29%）；35岁以下女性中有45例（36.88%）成功妊娠，35岁以上女性中有13例（15.66%）成功妊娠。考虑到卵泡>18 mm、受精的卵母细胞和胚胎数量在不同组之间存在差异，这些数字与女性年龄呈正相关。关于感兴趣的参数，我们记录到第3天时卵泡>18 mm的有1719个，回收的卵母细胞有1279个，胚胎有677个。另一方面，35岁以上女性的相应数字为：卵泡>18 mm的有814个，回收的卵母细胞有612个，第3天时胚胎有301个。在本研究期间，我们仅记录到3例流产（35岁以下女性中有1例，占0.81%；35岁以上女性中有2例，占2.40%）。35岁以下女性中有9例妊娠（7.37%）进展停止，35岁以下女性中有12例妊娠（35岁以下女性中有8例，占6.55%，35岁以上女性中有4例）未成功。35岁以上女性中有1例双胎妊娠得到确认（1.20%），35岁以下女性中有6例正在进行的妊娠（4.91%），在既定研究间隔结束时，两组均有2例（每组1例，35岁以下女性中占0.81%，35岁以上女性中占1.20%）妊娠结果不明。然而，也有治疗引起过度反应或无效的情况；有2例无反应者，1例出现中度卵巢过度刺激综合征（OHSS）。
基于我们的研究结果，我们强烈鼓励更广泛地使用这种重组促性腺激素。
